DD223452A5 - Verfahren zur herstellung von piperidinochinazolinen - Google Patents
Verfahren zur herstellung von piperidinochinazolinen Download PDFInfo
- Publication number
- DD223452A5 DD223452A5 DD84265888A DD26588884A DD223452A5 DD 223452 A5 DD223452 A5 DD 223452A5 DD 84265888 A DD84265888 A DD 84265888A DD 26588884 A DD26588884 A DD 26588884A DD 223452 A5 DD223452 A5 DD 223452A5
- Authority
- DD
- German Democratic Republic
- Prior art keywords
- compound
- formula
- dioxide
- group
- give
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title claims description 34
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 19
- 125000003386 piperidinyl group Chemical group 0.000 claims abstract description 10
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 7
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 4
- 125000002947 alkylene group Chemical group 0.000 claims abstract description 3
- 150000001875 compounds Chemical class 0.000 claims description 63
- 238000000034 method Methods 0.000 claims description 31
- 150000003839 salts Chemical class 0.000 claims description 20
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 7
- 150000001450 anions Chemical class 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 125000006239 protecting group Chemical group 0.000 claims description 4
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 claims description 2
- RSPISYXLHRIGJD-UHFFFAOYSA-N OOOO Chemical compound OOOO RSPISYXLHRIGJD-UHFFFAOYSA-N 0.000 claims 1
- 239000012024 dehydrating agents Substances 0.000 claims 1
- XGYCWCIGCYGQFU-UHFFFAOYSA-N 1,2-thiazolidine 1,1-dioxide Chemical group O=S1(=O)CCCN1 XGYCWCIGCYGQFU-UHFFFAOYSA-N 0.000 abstract description 8
- 229910052757 nitrogen Inorganic materials 0.000 abstract description 7
- FUSWEIKLDYAKEC-UHFFFAOYSA-N 2h-1,2,6-thiadiazine 1,1-dioxide Chemical group O=S1(=O)NC=CC=N1 FUSWEIKLDYAKEC-UHFFFAOYSA-N 0.000 abstract description 3
- 206010019280 Heart failures Diseases 0.000 abstract description 3
- 238000011282 treatment Methods 0.000 abstract description 3
- 125000004432 carbon atom Chemical group C* 0.000 abstract description 2
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 abstract description 2
- 239000000496 cardiotonic agent Substances 0.000 abstract description 2
- 239000002571 phosphodiesterase inhibitor Substances 0.000 abstract description 2
- ADBZIZGMAVRJPN-UHFFFAOYSA-N 1,2,5-thiadiazolidine 1,1-dioxide Chemical group O=S1(=O)NCCN1 ADBZIZGMAVRJPN-UHFFFAOYSA-N 0.000 abstract 1
- VIMMTIWARBDYNN-UHFFFAOYSA-N 4-piperidin-1-ylquinazoline Chemical class C1CCCCN1C1=NC=NC2=CC=CC=C12 VIMMTIWARBDYNN-UHFFFAOYSA-N 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- KISXBSWDCSYUKO-UHFFFAOYSA-N thiadiazinane 1,1-dioxide Chemical group O=S1(=O)CCCNN1 KISXBSWDCSYUKO-UHFFFAOYSA-N 0.000 abstract 1
- DNGMYXZLJGHHOM-UHFFFAOYSA-N thiazinane 1,1-dioxide Chemical group O=S1(=O)CCCCN1 DNGMYXZLJGHHOM-UHFFFAOYSA-N 0.000 abstract 1
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 102
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 78
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 67
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 57
- 239000000243 solution Substances 0.000 description 57
- 239000000203 mixture Substances 0.000 description 51
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 48
- -1 1 - (6,7-dimethoxy-quinazolin-4-yl) piperid-4-yl Chemical group 0.000 description 43
- 239000003921 oil Substances 0.000 description 43
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 38
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 36
- 238000004458 analytical method Methods 0.000 description 32
- 239000012458 free base Substances 0.000 description 32
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 25
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 24
- 239000007858 starting material Substances 0.000 description 24
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 23
- 239000000463 material Substances 0.000 description 23
- 239000000377 silicon dioxide Substances 0.000 description 23
- 229910000104 sodium hydride Inorganic materials 0.000 description 19
- 238000010992 reflux Methods 0.000 description 18
- 239000007787 solid Substances 0.000 description 18
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 16
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 15
- 239000006260 foam Substances 0.000 description 14
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 14
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 12
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 12
- 239000000284 extract Substances 0.000 description 12
- 239000012312 sodium hydride Substances 0.000 description 12
- RKOTXQYWCBGZLP-UHFFFAOYSA-N N-[(2,4-difluorophenyl)methyl]-2-ethyl-9-hydroxy-3-methoxy-1,8-dioxospiro[3H-pyrido[1,2-a]pyrazine-4,3'-oxolane]-7-carboxamide Chemical compound CCN1C(OC)C2(CCOC2)N2C=C(C(=O)NCC3=C(F)C=C(F)C=C3)C(=O)C(O)=C2C1=O RKOTXQYWCBGZLP-UHFFFAOYSA-N 0.000 description 11
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 239000000725 suspension Substances 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 239000008346 aqueous phase Substances 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- 239000012074 organic phase Substances 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 8
- 101150065749 Churc1 gene Proteins 0.000 description 8
- 102100038239 Protein Churchill Human genes 0.000 description 8
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical class [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 8
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 8
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 7
- 239000006185 dispersion Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 239000012279 sodium borohydride Substances 0.000 description 7
- 229910000033 sodium borohydride Inorganic materials 0.000 description 7
- 239000003039 volatile agent Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- 239000010779 crude oil Substances 0.000 description 6
- 125000000623 heterocyclic group Chemical group 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 6
- 239000003960 organic solvent Substances 0.000 description 6
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 6
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 6
- 229910052708 sodium Inorganic materials 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- LLLHRNQLGUOJHP-UHFFFAOYSA-N 4-chloro-6,7-dimethoxyquinazoline Chemical compound C1=NC(Cl)=C2C=C(OC)C(OC)=CC2=N1 LLLHRNQLGUOJHP-UHFFFAOYSA-N 0.000 description 5
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 150000003053 piperidines Chemical class 0.000 description 5
- 239000011698 potassium fluoride Substances 0.000 description 5
- 235000009518 sodium iodide Nutrition 0.000 description 5
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 230000000747 cardiac effect Effects 0.000 description 4
- 230000008602 contraction Effects 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- 230000002861 ventricular Effects 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- NZVZVGPYTICZBZ-UHFFFAOYSA-N 1-benzylpiperidine Chemical class C=1C=CC=CC=1CN1CCCCC1 NZVZVGPYTICZBZ-UHFFFAOYSA-N 0.000 description 3
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 3
- DOOKOJYYAWBLHD-UHFFFAOYSA-N 5-methyl-2-propyl-1,2,6-thiadiazinane 1,1-dioxide Chemical compound CCCN1CCC(C)NS1(=O)=O DOOKOJYYAWBLHD-UHFFFAOYSA-N 0.000 description 3
- ANNPUCMVTVIJGR-UHFFFAOYSA-N CCCN1C=CC(=NS1(=O)=O)C Chemical compound CCCN1C=CC(=NS1(=O)=O)C ANNPUCMVTVIJGR-UHFFFAOYSA-N 0.000 description 3
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 230000000297 inotrophic effect Effects 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 229910052744 lithium Inorganic materials 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 3
- 239000013081 microcrystal Substances 0.000 description 3
- 230000002107 myocardial effect Effects 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 125000005936 piperidyl group Chemical group 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 235000003270 potassium fluoride Nutrition 0.000 description 3
- 150000003222 pyridines Chemical class 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 3
- 235000013024 sodium fluoride Nutrition 0.000 description 3
- 239000011775 sodium fluoride Substances 0.000 description 3
- 159000000000 sodium salts Chemical class 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- BPLKQGGAXWRFOE-UHFFFAOYSA-M trimethylsulfoxonium iodide Chemical compound [I-].C[S+](C)(C)=O BPLKQGGAXWRFOE-UHFFFAOYSA-M 0.000 description 3
- SMTSLQBSVWAUAL-QXZBBMFGSA-N (3s,4s)-1-benzyl-4-(1-trityloxypropan-2-yl)piperidin-3-ol Chemical compound CC([C@H]1[C@@H](CN(CC=2C=CC=CC=2)CC1)O)COC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 SMTSLQBSVWAUAL-QXZBBMFGSA-N 0.000 description 2
- AFHFHXVRHACYSR-UHFFFAOYSA-N 1-pyridin-4-ylpropan-1-one Chemical compound CCC(=O)C1=CC=NC=C1 AFHFHXVRHACYSR-UHFFFAOYSA-N 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- JECYNCQXXKQDJN-UHFFFAOYSA-N 2-(2-methylhexan-2-yloxymethyl)oxirane Chemical compound CCCCC(C)(C)OCC1CO1 JECYNCQXXKQDJN-UHFFFAOYSA-N 0.000 description 2
- MEWOOKCAVBNRHE-UHFFFAOYSA-N 2-propyl-1,2-thiazolidine 1,1-dioxide Chemical compound CCCN1CCCS1(=O)=O MEWOOKCAVBNRHE-UHFFFAOYSA-N 0.000 description 2
- BPNFTOHKJKYSQX-UHFFFAOYSA-N 2-pyridin-4-ylpropane-1,2-diol Chemical compound OCC(O)(C)C1=CC=NC=C1 BPNFTOHKJKYSQX-UHFFFAOYSA-N 0.000 description 2
- JYEOYMRELWFASU-UHFFFAOYSA-N 3-methyl-2h-1,2,6-thiadiazine 1,1-dioxide Chemical compound CC1=CC=NS(=O)(=O)N1 JYEOYMRELWFASU-UHFFFAOYSA-N 0.000 description 2
- YDLMKTPSHWLJQK-UHFFFAOYSA-N 5-methyl-2-propylthiadiazinane 1,1-dioxide Chemical compound C(CC)N1S(CC(CN1)C)(=O)=O YDLMKTPSHWLJQK-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 229910010082 LiAlH Inorganic materials 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- 241000009298 Trigla lyra Species 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000001715 carotid artery Anatomy 0.000 description 2
- 239000002026 chloroform extract Substances 0.000 description 2
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000009109 curative therapy Methods 0.000 description 2
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- AQTNNBFADJJIQX-UHFFFAOYSA-N ethyl 2-(1-benzylpiperidin-4-ylidene)propanoate Chemical compound C1CC(=C(C)C(=O)OCC)CCN1CC1=CC=CC=C1 AQTNNBFADJJIQX-UHFFFAOYSA-N 0.000 description 2
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 210000002837 heart atrium Anatomy 0.000 description 2
- 150000002391 heterocyclic compounds Chemical class 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 2
- 230000000269 nucleophilic effect Effects 0.000 description 2
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 229910003446 platinum oxide Inorganic materials 0.000 description 2
- 230000009090 positive inotropic effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical compound C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 description 2
- LEHBURLTIWGHEM-UHFFFAOYSA-N pyridinium chlorochromate Chemical compound [O-][Cr](Cl)(=O)=O.C1=CC=[NH+]C=C1 LEHBURLTIWGHEM-UHFFFAOYSA-N 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- CSRZQMIRAZTJOY-UHFFFAOYSA-N trimethylsilyl iodide Chemical compound C[Si](C)(C)I CSRZQMIRAZTJOY-UHFFFAOYSA-N 0.000 description 2
- 238000001665 trituration Methods 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- KMGOVUGDZWPUII-JQXSQYPDSA-N (3s,4s)-1-benzyl-4-(1-hydroxypropan-2-yl)piperidin-3-ol Chemical compound C1[C@@H](O)[C@H](C(CO)C)CCN1CC1=CC=CC=C1 KMGOVUGDZWPUII-JQXSQYPDSA-N 0.000 description 1
- BHUSIWDXIKCGJM-UONOGXRCSA-N (3s,4s)-1-benzyl-4-(2-hydroxyethyl)piperidin-3-ol Chemical compound C1[C@@H](O)[C@H](CCO)CCN1CC1=CC=CC=C1 BHUSIWDXIKCGJM-UONOGXRCSA-N 0.000 description 1
- XOHLZRHJILLMED-GMCHKSTQSA-N (3s,4s)-1-benzyl-4-(2-trityloxyethyl)piperidin-3-ol Chemical compound C([C@H]([C@@H](CC1)CCOC(C=2C=CC=CC=2)(C=2C=CC=CC=2)C=2C=CC=CC=2)O)N1CC1=CC=CC=C1 XOHLZRHJILLMED-GMCHKSTQSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- ZTTPDEBBWJUCQQ-UHFFFAOYSA-N 1-(1-benzylpiperidin-4-yl)ethanone Chemical compound C1CC(C(=O)C)CCN1CC1=CC=CC=C1 ZTTPDEBBWJUCQQ-UHFFFAOYSA-N 0.000 description 1
- RDUPAYSTFGBUDB-UHFFFAOYSA-N 1-(1-quinazolin-2-ylpiperidin-4-yl)ethanone Chemical compound CC(=O)C1CCN(CC1)c1ncc2ccccc2n1 RDUPAYSTFGBUDB-UHFFFAOYSA-N 0.000 description 1
- SJZKULRDWHPHGG-UHFFFAOYSA-N 1-benzylpiperidin-4-one Chemical compound C1CC(=O)CCN1CC1=CC=CC=C1 SJZKULRDWHPHGG-UHFFFAOYSA-N 0.000 description 1
- UTDASSAGFYGOJT-UHFFFAOYSA-N 1-chloro-2-pyridin-4-ylpropan-2-ol Chemical compound ClCC(O)(C)C1=CC=NC=C1 UTDASSAGFYGOJT-UHFFFAOYSA-N 0.000 description 1
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 description 1
- WDOWPHYNSYXXHJ-UHFFFAOYSA-N 1-piperidin-4-ylpropan-1-ol Chemical compound CCC(O)C1CCNCC1 WDOWPHYNSYXXHJ-UHFFFAOYSA-N 0.000 description 1
- WMQUKDQWMMOHSA-UHFFFAOYSA-N 1-pyridin-4-ylethanone Chemical compound CC(=O)C1=CC=NC=C1 WMQUKDQWMMOHSA-UHFFFAOYSA-N 0.000 description 1
- JDIIGWSSTNUWGK-UHFFFAOYSA-N 1h-imidazol-3-ium;chloride Chemical compound [Cl-].[NH2+]1C=CN=C1 JDIIGWSSTNUWGK-UHFFFAOYSA-N 0.000 description 1
- FTBGRBGHTJJDDQ-UHFFFAOYSA-N 2-(1-benzyl-3,6-dihydro-2h-pyridin-4-yl)propan-1-ol Chemical compound C1CC(C(CO)C)=CCN1CC1=CC=CC=C1 FTBGRBGHTJJDDQ-UHFFFAOYSA-N 0.000 description 1
- NQIBQILAMKZKFE-UHFFFAOYSA-N 2-(5-bromo-2-fluorophenyl)-3-fluoropyridine Chemical compound FC1=CC=C(Br)C=C1C1=NC=CC=C1F NQIBQILAMKZKFE-UHFFFAOYSA-N 0.000 description 1
- PDLJUZXPVBIAOE-HRAATJIYSA-N 2-[(3S,4S)-3-[tert-butyl(dimethyl)silyl]oxy-1-(6,7-dimethoxyquinazolin-4-yl)piperidin-4-yl]ethanol Chemical compound COC=1C=C2C(=NC=NC2=CC=1OC)N1C[C@H]([C@@H](CC1)CCO)O[Si](C)(C)C(C)(C)C PDLJUZXPVBIAOE-HRAATJIYSA-N 0.000 description 1
- HWRSCEOMSMHPTB-NWDGAFQWSA-N 2-[(3S,4S)-3-[tert-butyl(dimethyl)silyl]oxypiperidin-4-yl]ethanol Chemical compound [Si](C)(C)(C(C)(C)C)O[C@@H]1CNCC[C@H]1CCO HWRSCEOMSMHPTB-NWDGAFQWSA-N 0.000 description 1
- BDZPUIXYWOXXRG-LWNNLKQOSA-N 2-[(3S,4S)-3-[tert-butyl(dimethyl)silyl]oxypiperidin-4-yl]propan-1-ol Chemical compound [Si](C)(C)(C(C)(C)C)O[C@@H]1CNCC[C@H]1C(CO)C BDZPUIXYWOXXRG-LWNNLKQOSA-N 0.000 description 1
- IVKMZOGWDCFHBI-UHFFFAOYSA-N 2-[2-(1,2,3,6-tetrahydropyridin-4-yl)ethyl]-1,2-thiazolidine 1,1-dioxide Chemical compound O=S1(=O)CCCN1CCC1=CCNCC1 IVKMZOGWDCFHBI-UHFFFAOYSA-N 0.000 description 1
- GYMTUXHRQWJXMW-UHFFFAOYSA-N 2-piperidin-1-ylquinazoline Chemical class C1CCCCN1C1=NC=C(C=CC=C2)C2=N1 GYMTUXHRQWJXMW-UHFFFAOYSA-N 0.000 description 1
- GLSVKJBMRJQQCE-UHFFFAOYSA-N 2-piperidin-4-ylpropane-1,2-diol Chemical compound OCC(O)(C)C1CCNCC1 GLSVKJBMRJQQCE-UHFFFAOYSA-N 0.000 description 1
- PDXCOWCINSIDPO-UHFFFAOYSA-N 2h-thiadiazine 1,1-dioxide Chemical compound O=S1(=O)NN=CC=C1 PDXCOWCINSIDPO-UHFFFAOYSA-N 0.000 description 1
- WIOBMVCWYCJKOW-UHFFFAOYSA-N 4-(2-ethyloxiran-2-yl)pyridine Chemical compound C=1C=NC=CC=1C1(CC)CO1 WIOBMVCWYCJKOW-UHFFFAOYSA-N 0.000 description 1
- TVWOMZDFIAIZIE-UHFFFAOYSA-N 4-(4-ethylpiperidin-1-yl)-6,7-dimethoxyquinazoline Chemical compound C1CC(CC)CCN1C1=NC=NC2=CC(OC)=C(OC)C=C12 TVWOMZDFIAIZIE-UHFFFAOYSA-N 0.000 description 1
- MPZMVUQGXAOJIK-UHFFFAOYSA-N 4-bromopyridine;hydron;chloride Chemical compound Cl.BrC1=CC=NC=C1 MPZMVUQGXAOJIK-UHFFFAOYSA-N 0.000 description 1
- MPMPYHKTFSOUHU-UHFFFAOYSA-N 4-prop-1-en-2-ylpyridine Chemical compound CC(=C)C1=CC=NC=C1 MPMPYHKTFSOUHU-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- JQDFDWSWYPNEBD-UHFFFAOYSA-N CC1=NS(=O)(=O)NC=C1 Chemical compound CC1=NS(=O)(=O)NC=C1 JQDFDWSWYPNEBD-UHFFFAOYSA-N 0.000 description 1
- 206010007556 Cardiac failure acute Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 239000004146 Propane-1,2-diol Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical group ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 1
- DKRQLRHWROROAM-JPJFQPDVSA-N [(3S,4S)-1-benzyl-4-(1-trityloxypropan-2-yl)piperidin-3-yl]oxy-tert-butyl-dimethylsilane Chemical compound C(C1=CC=CC=C1)N1C[C@H]([C@@H](CC1)C(COC(C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1)C)O[Si](C)(C)C(C)(C)C DKRQLRHWROROAM-JPJFQPDVSA-N 0.000 description 1
- AECJEZURRQMTFC-DYKQPOOOSA-N [(3S,4S)-1-benzyl-4-(2-trityloxyethyl)piperidin-3-yl]oxy-tert-butyl-dimethylsilane Chemical compound C(C1=CC=CC=C1)N1C[C@H]([C@@H](CC1)CCOC(C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1)O[Si](C)(C)C(C)(C)C AECJEZURRQMTFC-DYKQPOOOSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- LRJRPHROCLHMHK-UHFFFAOYSA-N boron;n,n-dimethylmethanamine Chemical compound [B].CN(C)C LRJRPHROCLHMHK-UHFFFAOYSA-N 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- BULLHNJGPPOUOX-UHFFFAOYSA-N chloroacetone Chemical compound CC(=O)CCl BULLHNJGPPOUOX-UHFFFAOYSA-N 0.000 description 1
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
- DDKMFOUTRRODRE-UHFFFAOYSA-N chloromethanone Chemical compound Cl[C]=O DDKMFOUTRRODRE-UHFFFAOYSA-N 0.000 description 1
- ZCDOYSPFYFSLEW-UHFFFAOYSA-N chromate(2-) Chemical compound [O-][Cr]([O-])(=O)=O ZCDOYSPFYFSLEW-UHFFFAOYSA-N 0.000 description 1
- 230000002057 chronotropic effect Effects 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000006264 debenzylation reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical compound [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- URZCLFHCFZFWMH-UHFFFAOYSA-N ethyl 2-(1-benzyl-3,6-dihydro-2h-pyridin-4-yl)acetate Chemical compound C1CC(CC(=O)OCC)=CCN1CC1=CC=CC=C1 URZCLFHCFZFWMH-UHFFFAOYSA-N 0.000 description 1
- BVSRWCMAJISCTD-UHFFFAOYSA-N ethyl 2-diethoxyphosphorylpropanoate Chemical compound CCOC(=O)C(C)P(=O)(OCC)OCC BVSRWCMAJISCTD-UHFFFAOYSA-N 0.000 description 1
- UNPNCTBMHIAWLL-UHFFFAOYSA-N ethyl 3-(1-benzyl-3,6-dihydro-2h-pyridin-4-yl)propanoate Chemical compound C1CC(CCC(=O)OCC)=CCN1CC1=CC=CC=C1 UNPNCTBMHIAWLL-UHFFFAOYSA-N 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229960001317 isoprenaline Drugs 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- XMJHPCRAQCTCFT-UHFFFAOYSA-N methyl chloroformate Chemical compound COC(Cl)=O XMJHPCRAQCTCFT-UHFFFAOYSA-N 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 150000002924 oxiranes Chemical class 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- BIWOSRSKDCZIFM-UHFFFAOYSA-N piperidin-3-ol Chemical compound OC1CCCNC1 BIWOSRSKDCZIFM-UHFFFAOYSA-N 0.000 description 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 150000003246 quinazolines Chemical class 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000006104 solid solution Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- QGHFKDWXEKWJJO-QUUZRVDCSA-N tert-butyl-[(3S,4S)-1-(6,7-dimethoxyquinazolin-4-yl)-4-(1-iodopropan-2-yl)piperidin-3-yl]oxy-dimethylsilane Chemical compound COC=1C=C2C(=NC=NC2=CC=1OC)N1C[C@H]([C@@H](CC1)C(CI)C)O[Si](C)(C)C(C)(C)C QGHFKDWXEKWJJO-QUUZRVDCSA-N 0.000 description 1
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- NHGXDBSUJJNIRV-UHFFFAOYSA-M tetrabutylammonium chloride Chemical class [Cl-].CCCC[N+](CCCC)(CCCC)CCCC NHGXDBSUJJNIRV-UHFFFAOYSA-M 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- 125000005424 tosyloxy group Chemical group S(=O)(=O)(C1=CC=C(C)C=C1)O* 0.000 description 1
- VFJYIHQDILEQNR-UHFFFAOYSA-M trimethylsulfanium;iodide Chemical compound [I-].C[S+](C)C VFJYIHQDILEQNR-UHFFFAOYSA-M 0.000 description 1
- JBWKIWSBJXDJDT-UHFFFAOYSA-N triphenylmethyl chloride Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(Cl)C1=CC=CC=C1 JBWKIWSBJXDJDT-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/42—Oxygen atoms attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Hydrogenated Pyridines (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB838320958A GB8320958D0 (en) | 1983-08-03 | 1983-08-03 | Quinazoline cardiac stimulants |
Publications (1)
Publication Number | Publication Date |
---|---|
DD223452A5 true DD223452A5 (de) | 1985-06-12 |
Family
ID=10546755
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DD84265888A DD223452A5 (de) | 1983-08-03 | 1984-08-01 | Verfahren zur herstellung von piperidinochinazolinen |
Country Status (22)
Country | Link |
---|---|
US (1) | US4542132A (el) |
EP (1) | EP0135318B1 (el) |
JP (1) | JPS6069081A (el) |
KR (1) | KR870000905B1 (el) |
AU (1) | AU555482B2 (el) |
CS (1) | CS253714B2 (el) |
DD (1) | DD223452A5 (el) |
DE (1) | DE3472677D1 (el) |
DK (1) | DK375584A (el) |
ES (1) | ES8507536A1 (el) |
FI (1) | FI843047A (el) |
GB (1) | GB8320958D0 (el) |
GR (1) | GR82659B (el) |
HU (1) | HUT37421A (el) |
IL (1) | IL72562A (el) |
NO (1) | NO158941C (el) |
NZ (1) | NZ209095A (el) |
PH (1) | PH20835A (el) |
PL (1) | PL249025A1 (el) |
PT (1) | PT79001B (el) |
YU (1) | YU135884A (el) |
ZA (1) | ZA845944B (el) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61215389A (ja) * | 1985-03-20 | 1986-09-25 | Kyowa Hakko Kogyo Co Ltd | キナゾリン誘導体およびそれを含有する強心剤 |
FR2582513B1 (fr) * | 1985-05-28 | 1988-08-05 | Synthelabo | Compositions pharmaceutiques contenant de l'alfuzosine |
US5614627A (en) * | 1993-09-10 | 1997-03-25 | Eisai Co., Ltd. | Quinazoline compounds |
US8071768B2 (en) * | 2005-06-10 | 2011-12-06 | Janssen Pharmaceutica, N.V. | Alkylquinoline and alkylquinazoline kinase modulators |
US7825244B2 (en) * | 2005-06-10 | 2010-11-02 | Janssen Pharmaceutica Nv | Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis |
JP2009213594A (ja) * | 2008-03-10 | 2009-09-24 | Okamura Chikuzai:Kk | 葬祭用祭壇装置 |
CN104860870A (zh) * | 2014-02-26 | 2015-08-26 | 欧美嘉股份有限公司 | 具有不同取代基的哌啶的制备方法 |
EP4097089A4 (en) * | 2020-01-31 | 2024-02-28 | Trinapco, Inc | TRIFLAZOLES AND THEIR PRODUCTION PROCESS |
US11294401B2 (en) | 2020-07-08 | 2022-04-05 | Saudi Arabian Oil Company | Flow management systems and related methods for oil and gas applications |
US11314266B2 (en) | 2020-07-08 | 2022-04-26 | Saudi Arabian Oil Company | Flow management systems and related methods for oil and gas applications |
US11131158B1 (en) | 2020-07-08 | 2021-09-28 | Saudi Arabian Oil Company | Flow management systems and related methods for oil and gas applications |
US11256273B2 (en) | 2020-07-08 | 2022-02-22 | Saudi Arabian Oil Company | Flow management systems and related methods for oil and gas applications |
US11802645B2 (en) | 2020-07-08 | 2023-10-31 | Saudi Arabian Oil Company | Flow management systems and related methods for oil and gas applications |
US11274501B2 (en) | 2020-07-08 | 2022-03-15 | Saudi Arabian Oil Company | Flow management systems and related methods for oil and gas applications |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3517005A (en) * | 1967-10-26 | 1970-06-23 | Pfizer & Co C | Certain 2- and 4-substituted quinazolines |
US4101548A (en) * | 1977-02-22 | 1978-07-18 | Bristol-Myers Company | 1,2,3-Thiadiazole amides |
IN148482B (el) * | 1977-06-03 | 1981-03-07 | Pfizer | |
US4370328A (en) * | 1977-11-03 | 1983-01-25 | Pfizer Inc. | Cardiac stimulant 1-(3- or 4-substituted piperidino)phthalazines |
US4188390A (en) * | 1977-11-05 | 1980-02-12 | Pfizer Inc. | Antihypertensive 4-amino-2-[4-(1,4-benzodioxan-2-carbonyl) piperazin-1-yl or homopiperazin-1-yl]quinazolines |
US4489075A (en) * | 1982-05-15 | 1984-12-18 | Pfizer Inc. | Cyclic sulfonamidoalkyl substituted 4-piperidinoquinazoline cardiac stimulants |
-
1983
- 1983-08-03 GB GB838320958A patent/GB8320958D0/en active Pending
-
1984
- 1984-07-30 PT PT79001A patent/PT79001B/pt unknown
- 1984-07-30 EP EP84305151A patent/EP0135318B1/en not_active Expired
- 1984-07-30 DE DE8484305151T patent/DE3472677D1/de not_active Expired
- 1984-07-31 GR GR75460A patent/GR82659B/el unknown
- 1984-07-31 JP JP59161498A patent/JPS6069081A/ja active Pending
- 1984-07-31 US US06/636,197 patent/US4542132A/en not_active Expired - Lifetime
- 1984-08-01 IL IL72562A patent/IL72562A/xx unknown
- 1984-08-01 DD DD84265888A patent/DD223452A5/de unknown
- 1984-08-01 ZA ZA845944A patent/ZA845944B/xx unknown
- 1984-08-01 PL PL24902584A patent/PL249025A1/xx unknown
- 1984-08-01 FI FI843047A patent/FI843047A/fi not_active Application Discontinuation
- 1984-08-01 YU YU01358/84A patent/YU135884A/xx unknown
- 1984-08-01 PH PH31057A patent/PH20835A/en unknown
- 1984-08-02 NZ NZ209095A patent/NZ209095A/xx unknown
- 1984-08-02 KR KR1019840004616A patent/KR870000905B1/ko active IP Right Grant
- 1984-08-02 HU HU842948A patent/HUT37421A/hu unknown
- 1984-08-02 DK DK375584A patent/DK375584A/da not_active Application Discontinuation
- 1984-08-02 NO NO843117A patent/NO158941C/no unknown
- 1984-08-02 ES ES534824A patent/ES8507536A1/es not_active Expired
- 1984-08-02 AU AU31419/84A patent/AU555482B2/en not_active Ceased
- 1984-08-03 CS CS845918A patent/CS253714B2/cs unknown
Also Published As
Publication number | Publication date |
---|---|
DK375584A (da) | 1985-02-04 |
FI843047A (fi) | 1985-02-04 |
IL72562A0 (en) | 1984-11-30 |
YU135884A (en) | 1986-10-31 |
CS253714B2 (en) | 1987-12-17 |
ES534824A0 (es) | 1985-09-01 |
DK375584D0 (da) | 1984-08-02 |
ES8507536A1 (es) | 1985-09-01 |
AU555482B2 (en) | 1986-09-25 |
AU3141984A (en) | 1985-02-07 |
NO158941B (no) | 1988-08-08 |
FI843047A0 (fi) | 1984-08-01 |
EP0135318A1 (en) | 1985-03-27 |
PT79001B (en) | 1986-10-23 |
EP0135318B1 (en) | 1988-07-13 |
NO158941C (no) | 1988-11-16 |
CS591884A2 (en) | 1987-05-14 |
KR870000905B1 (ko) | 1987-05-04 |
NO843117L (no) | 1985-02-04 |
US4542132A (en) | 1985-09-17 |
PT79001A (en) | 1984-08-01 |
ZA845944B (en) | 1986-07-30 |
IL72562A (en) | 1987-03-31 |
PH20835A (en) | 1987-04-30 |
GB8320958D0 (en) | 1983-09-07 |
NZ209095A (en) | 1986-11-12 |
JPS6069081A (ja) | 1985-04-19 |
KR850001746A (ko) | 1985-04-01 |
DE3472677D1 (de) | 1988-08-18 |
PL249025A1 (en) | 1985-08-27 |
GR82659B (el) | 1985-02-07 |
HUT37421A (en) | 1985-12-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE2915037C3 (de) | Neue N-substituierte Moranolinderivate | |
DE69704679T2 (de) | 4-phenylpiperidin-derivate | |
DE3688827T2 (de) | Piperidinderivat, seine Herstellung und seine Verwendung als Arzneimittel. | |
DE2824064A1 (de) | Phthalazin-derivate, ihre herstellung und solche derivate enthaltende arzneimittel | |
DE2658544A1 (de) | Carbostyrilderivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel | |
DE3784401T2 (de) | Karbostyril-derivate und ihre salze, verfahren zu ihrer herstellung und diese enthaltende kardiotonische zusammensetzung. | |
DE3788982T2 (de) | Trans-6-[2-(N-heteroaryl)-3,5-disubstituiertes)pyrazol-4-yl)-ethyl] oder -ethenyl]tetrahydro-4-hydroxypyran-2-on-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung. | |
DE3612337A1 (de) | 4h-1-benzopyran-4-on-derivate, ein verfahren zu ihrer herstellung und ihre verwendung als arzneimittel | |
DD223452A5 (de) | Verfahren zur herstellung von piperidinochinazolinen | |
DE69329894T2 (de) | Arylamidderivate | |
DE2555590A1 (de) | 1-substituierte-4-benzylidenpiperidine und verfahren zu ihrer herstellung | |
DD213920A5 (de) | Verfahren zur herstellung von dihydropyridinen | |
EP1368313B1 (de) | Verfahren zur herstellung von nicht hydratisiertem fexofenadin-hydrochlorid in form eines neuen polymorphs | |
DE2847621A1 (de) | Phthalazin-derivate, verfahren zu ihrer herstellung und solche derivate enthaltende arzneimittel | |
DE69126433T2 (de) | 1,4-disubstituierte piperazine | |
DD290186A5 (de) | Verfahren zur herstellung von piperidinderivaten | |
DE69202120T2 (de) | Harnstoffderivate, ihre Herstellung und ihre Verwendung bei der Therapie. | |
DE1445836A1 (de) | Verfahren zur Herstellung von neuen Derivaten des 1,2,3,6-Tetrahydro-pyridins | |
DE2313258A1 (de) | Verfahren zur herstellung von butyrophenonderivaten und ihren salzen neue butyrophenonderivate, ihre salze und diese verbindungen enthaltende arzneimittel | |
DE2919800A1 (de) | 4-amino-2-piperidinochinazolin-derivate, verfahren zu ihrer herstellung und solche derivate enthaltende arzneimittel | |
DE2410938A1 (de) | Chinazolinderivate und diese enthaltende arzneimittel | |
DE60217934T2 (de) | Verfahren zur herstellung von desloratadin | |
DE4117750A1 (de) | Neue 2-amino-5-cyano-1,4-dihydropyridine, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln | |
DE2035573A1 (de) | Neue Imidazolderivate, ihre Herstellung und die sie enthaltenden medizinischen Zu sammensetzungen | |
DE68902064T2 (de) | Dihydropyridine und ihre verwendung als anti-allergische und entzuendungshemmende mittel. |